Literature DB >> 19519412

A critical review of analytical methods for subvisible and visible particles.

Linda O Narhi1, Yijia Jiang, Shawn Cao, Kalman Benedek, Deborah Shnek.   

Abstract

The subvisible and visible particles present in a solution are often classified based on size, and are quantified by the actual number of particles present rather than by weight or molar amounts. The analysis of these particles in protein therapeutics are governed by compendial methods and the regulatory agencies, and the methods available to measure them originally evolved focusing on potential safety issues, including capillary occlusion and immunogenicity, that might arise from their presence. Ultracentrifugation, size exclusion chromatography, etc., discussed in previous articles, can be used to analyze aggregates of less than 0.10 microns. This article will focus on methods for analyzing and quantitating sub visible particles (SbVP) of 2 microns or larger. At the present time there is no routine method for quantitating sub visible particles (SbVP) between 0.1 microns and 2 microns. The most common technique for quantitating the amount of subvisible particles between 2 and 100 microns is the light obscuration method. This technique can determine size and amount of particles, but cannot differentiate between the types of particles, such as protein particles, foreign material, micro bubbles or silicone oil droplets, that can be present in protein solutions. The difficulties in adapting this method, originally developed for small molecule drugs for IV administration, to protein therapeutics delivered subcutaneously is discussed. The flow imaging techniques can determine morphology and optical characteristics of the particles, but still not identify the chemical composition. Other methods that can also be used, but are applicable for characterization purposes only, are discussed. The primary method for quantitating visible particles is visual inspection, a method that can be subjective and relies on adequate training of the human inspectors. Automated methods for visible particle determination are being developed. Identification of the chemical composition of isolated particles greater than about 50 microns is possible using several micro-spectroscopic methods, and these will also be discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19519412     DOI: 10.2174/138920109788488905

Source DB:  PubMed          Journal:  Curr Pharm Biotechnol        ISSN: 1389-2010            Impact factor:   2.837


  18 in total

1.  Factors Governing the Precision of Subvisible Particle Measurement Methods - A Case Study with a Low-Concentration Therapeutic Protein Product in a Prefilled Syringe.

Authors:  Anacelia Ríos Quiroz; Jens Lamerz; Thierry Da Cunha; Adeline Boillon; Michael Adler; Christof Finkler; Joerg Huwyler; Roland Schmidt; Hanns-Christian Mahler; Atanas V Koulov
Journal:  Pharm Res       Date:  2015-10-16       Impact factor: 4.200

Review 2.  Protein particulate detection issues in biotherapeutics development--current status.

Authors:  Tapan K Das
Journal:  AAPS PharmSciTech       Date:  2012-05-08       Impact factor: 3.246

3.  Radar chart array analysis to visualize effects of formulation variables on IgG1 particle formation as measured by multiple analytical techniques.

Authors:  Cavan Kalonia; Ozan S Kumru; Jae Hyun Kim; C Russell Middaugh; David B Volkin
Journal:  J Pharm Sci       Date:  2013-10-09       Impact factor: 3.534

4.  Classification and characterization of therapeutic antibody aggregates.

Authors:  Marisa K Joubert; Quanzhou Luo; Yasser Nashed-Samuel; Jette Wypych; Linda O Narhi
Journal:  J Biol Chem       Date:  2011-03-25       Impact factor: 5.157

5.  Volume-based pollen size analysis: an advanced method to assess somatic and gametophytic ploidy in flowering plants.

Authors:  Nico De Storme; Linda Zamariola; Martin Mau; Timothy F Sharbel; Danny Geelen
Journal:  Plant Reprod       Date:  2013-01-11       Impact factor: 3.767

6.  Complexities of particulate matter measurement in parenteral formulations of small-molecule amphiphilic drugs.

Authors:  Magali B Hickey; Sara Waggener; Dilip Gole; Ilias Jimidar; Hans Vermeersch; Poe Ratanabanangkoon; Arjen P Tinke; Örn Almarsson
Journal:  AAPS PharmSciTech       Date:  2011-01-14       Impact factor: 3.246

7.  Phase-Appropriate Application of Analytical Methods to Monitor Subvisible Particles Across the Biotherapeutic Drug Product Life Cycle.

Authors:  Roman Mathaes; Linda Narhi; Andrea Hawe; Anja Matter; Karoline Bechtold-Peters; Sophia Kenrick; Sambit Kar; Olga Laskina; John Carpenter; Richard Cavicchi; Ellen Koepf; E Neil Lewis; Rukman De Silva; Dean Ripple
Journal:  AAPS J       Date:  2019-10-30       Impact factor: 4.009

8.  Transmission electron microscopy as an orthogonal method to characterize protein aggregates.

Authors:  Joyce J Sung; Neha N Pardeshi; Anke M Mulder; Sean K Mulligan; Joel Quispe; Kathy On; Bridget Carragher; Clinton S Potter; John F Carpenter; Anette Schneemann
Journal:  J Pharm Sci       Date:  2014-09-17       Impact factor: 3.534

9.  Development of biotechnology products in pre-filled syringes: technical considerations and approaches.

Authors:  Advait Badkar; Amanda Wolf; Leigh Bohack; Parag Kolhe
Journal:  AAPS PharmSciTech       Date:  2011-05-04       Impact factor: 3.246

Review 10.  Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars.

Authors:  Steven A Berkowitz; John R Engen; Jeffrey R Mazzeo; Graham B Jones
Journal:  Nat Rev Drug Discov       Date:  2012-06-29       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.